Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00880932 · ClinicalTrials.gov registry record · NA

Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

A NA study, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
1,865
Enrollment target

NCT00880932: Completed NA study, sponsored by University of Pennsylvania.

NCT00880932 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 1,865 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00880932, a NA study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
1,865 participants
Enrollment target

Study Summary

The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.

Interventions

  • BEHAVIORAL Electronic Alert

Trial Details

FieldValue
Enrollment Target 1,865 participants
Start Date 2006-08
Est. Completion 2007-12
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT00880932

The ClinicalTrials.gov registry entry for NCT00880932 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,865 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Electronic Alert is the first listed.

NCT00880932 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00880932 about?

NCT00880932 is a clinical study titled "Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert". The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribe...

What is the current status of trial NCT00880932?

This trial is currently completed. It is a NA study. The enrollment target is 1,865 participants. The study started on 2006-08. Estimated completion is 2007-12.

What interventions are being tested in trial NCT00880932?

The interventions under investigation include: Electronic Alert (BEHAVIORAL).

Who is sponsoring clinical trial NCT00880932?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.